The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
First-in-human study of autologous chimeric engulfment receptor T-cell CER-1236 targeting TIM-4-l in acute myeloid leukemia (CertainT-1).
 
Abhishek Maiti
Research Funding - Celgene (Inst); Chimeric Therapeutics (Inst); CytoMed Therapeutics (Inst); Indapta Therapeutics (Inst); Lin BioScience (Inst)
 
Jeremy Ramdial
No Relationships to Disclose
 
Brandon Cieniewicz
Employment - CERo Therapeutics Holdings, Inc
Stock and Other Ownership Interests - Merck
 
Edson Oliveira
Employment - CERo Therapeutics Holdings, Inc.
Stock and Other Ownership Interests - Fate Therapeutics; Poseida Therapeutics; Precision Biosciences
Travel, Accommodations, Expenses - CERo Therapeutics Holdings, Inc.
 
Ankit Bhatta
Employment - Cero Therapeutics Holdings Inc; Gilead Sciences (I)
Stock and Other Ownership Interests - Cero Therapeutics Holding Inc; Elicio Therapeutics; Gilead Sciences (I); Lilly; Merck; Novartis; Novo Nordisk
Research Funding - Cero Therapeutics; Gilead Sciences (I)
Travel, Accommodations, Expenses - Cero Therapeutics Holdings Inc.; Gilead Sciences (I)
 
Hongxiu Ning
No Relationships to Disclose
 
Yazan Migdady
Consulting or Advisory Role - Medexus Pharmaceuticals; Rigel; SERVIER
 
Jacob Appelbaum
Research Funding - 2seventy bio (Inst); Immunogen (Inst); Kura Oncology (Inst); Vincerx Pharma (Inst)
(OPTIONAL) Uncompensated Relationships - Regeneron